Danica Pension Livsforsikringsaktieselskab Purchases Shares of 1,385,990 Abbott Laboratories $ABT

Danica Pension Livsforsikringsaktieselskab acquired a new position in shares of Abbott Laboratories (NYSE:ABT) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,385,990 shares of the healthcare product maker’s stock, valued at approximately $185,640,000. Abbott Laboratories makes up about 2.9% of Danica Pension Livsforsikringsaktieselskab’s portfolio, making the stock its 9th largest holding.

Several other institutional investors have also added to or reduced their stakes in ABT. Charles Schwab Trust Co grew its position in Abbott Laboratories by 109.8% in the third quarter. Charles Schwab Trust Co now owns 29,412 shares of the healthcare product maker’s stock valued at $3,939,000 after purchasing an additional 15,394 shares in the last quarter. Asset Management One Co. Ltd. boosted its stake in shares of Abbott Laboratories by 2.4% during the 3rd quarter. Asset Management One Co. Ltd. now owns 858,834 shares of the healthcare product maker’s stock worth $115,032,000 after buying an additional 19,966 shares during the last quarter. Nordea Investment Management AB boosted its stake in shares of Abbott Laboratories by 6.1% during the 3rd quarter. Nordea Investment Management AB now owns 329,430 shares of the healthcare product maker’s stock worth $43,785,000 after buying an additional 18,974 shares during the last quarter. AE Wealth Management LLC grew its holdings in shares of Abbott Laboratories by 20.8% in the 3rd quarter. AE Wealth Management LLC now owns 65,504 shares of the healthcare product maker’s stock valued at $8,774,000 after acquiring an additional 11,264 shares in the last quarter. Finally, Mawer Investment Management Ltd. increased its position in shares of Abbott Laboratories by 5.9% in the third quarter. Mawer Investment Management Ltd. now owns 1,255,780 shares of the healthcare product maker’s stock valued at $168,199,000 after acquiring an additional 70,122 shares during the last quarter. 75.18% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently commented on ABT shares. The Goldman Sachs Group reduced their price target on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating for the company in a research report on Friday, January 23rd. Royal Bank Of Canada dropped their price objective on Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Oppenheimer cut their price objective on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Freedom Capital upgraded shares of Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 29th. Finally, Raymond James Financial dropped their price target on shares of Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $136.16.

Abbott Laboratories Price Performance

NYSE:ABT opened at $110.80 on Wednesday. Abbott Laboratories has a 12-month low of $105.27 and a 12-month high of $139.06. The firm has a market capitalization of $192.98 billion, a price-to-earnings ratio of 29.79, a P/E/G ratio of 1.75 and a beta of 0.74. The stock’s 50 day moving average price is $113.91 and its two-hundred day moving average price is $123.50. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting the consensus estimate of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The company had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. During the same period in the previous year, the company posted $1.34 EPS. The firm’s revenue for the quarter was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s payout ratio is currently 67.74%.

Insider Buying and Selling

In other news, SVP Eric Shroff sold 709 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $81,946.22. Following the transaction, the senior vice president directly owned 39,164 shares of the company’s stock, valued at $4,526,575.12. This represents a 1.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Daniel J. Starks bought 10,000 shares of Abbott Laboratories stock in a transaction that occurred on Wednesday, February 4th. The shares were bought at an average cost of $108.73 per share, with a total value of $1,087,300.00. Following the acquisition, the director directly owned 6,738,817 shares in the company, valued at $732,711,572.41. This trade represents a 0.15% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders sold 3,055 shares of company stock valued at $353,097. 0.46% of the stock is currently owned by insiders.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.